These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39206190)

  • 1. IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report.
    Terashima Y; Matsumoto M; Ozaki S; Nakagawa M; Nakagome S; Terasaki Y; Iida H; Mitsugi R; Kuramochi E; Okada N; Inoue T; Matsuki S; Kitagawa S; Fukuizumi A; Onda N; Takeuchi S; Miyanaga A; Kasahara K; Seike M
    Front Immunol; 2024; 15():1370972. PubMed ID: 39206190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
    Nakamichi S; Kubota K; Matsuyama K; Misumi T; Kozuki T; Sugawara S; Naoki K; Kobayashi N; Shukuya T; Shimokawa T; Ishihara M; Wakui H; Hosomi Y; Tanaka H; Saito H; Hosokawa S; Takiguchi Y; Kasai T; Nokihara H; Morita R; Aono H; Furuya N; Okamoto H
    Clin Lung Cancer; 2024 Jan; 25(1):85-90. PubMed ID: 37981477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.
    Nagata Y; Toyokawa G; Sugiyama A; Shimamatsu S; Saitoh O; Okubo H; Ueda H
    J Oncol Pharm Pract; 2024 Jun; 30(4):772-776. PubMed ID: 38404012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.
    Chen Y; Kang S; Yan M
    Pharmacol Res Perspect; 2022 Jun; 10(3):e00941. PubMed ID: 35568997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Matsubara T; Uchi H; Haratake N; Takamori S; Toyozawa R; Miura N; Yamaguchi M; Seto T; Takenoyama M
    Clin Lung Cancer; 2020 Mar; 21(2):e54-e56. PubMed ID: 31874730
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
    Yang JJ; Huang C; Chen GY; Song Y; Cheng Y; Yan HH; Zhou Q; Wu YL
    BMC Cancer; 2014 Sep; 14():684. PubMed ID: 25239521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
    N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
    Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
    Sakaguchi K; Kosaka M; Yamazaki Y
    Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
    Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
    Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction.
    Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
    Intern Med; 2024 Aug; 63(15):2163-2166. PubMed ID: 38104995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
    Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
    Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
    Wang Z; Huang C; Yang JJ; Song Y; Cheng Y; Chen GY; Yan HH; Ben XS; Wang BC; Xu CR; Jiang BY; Zhou Q; Chen HJ; Wu YL
    Eur J Cancer; 2019 Mar; 109():183-191. PubMed ID: 30739019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.